Injection site number and outcomes of intradetrusor onabotulinumtoxinA for refractory overactive bladder syndrome: a randomized clinical trial.

Zdroik, Anna; El Haraki, Amr; Smith, Whitney; Badlani, Gopal; Parker-Autry, Candace; Matthews, Catherine

Zdroik, Anna; El Haraki, Amr; Smith, Whitney; Badlani, Gopal; Parker-Autry, Candace; Matthews, Catherine.

Afiliación

Zdroik A; Department of Urology, Atrium Health Wake Forest Baptist Hospital, 1 Medical Center Boulevard, Winston-Salem, NC, 27101, USA.
El Haraki A; Department of Urology, Atrium Health Wake Forest Baptist Hospital, 1 Medical Center Boulevard, Winston-Salem, NC, 27101, USA.
Smith W; Department of Urology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
Badlani G; Department of Urology, Atrium Health Wake Forest Baptist Hospital, 1 Medical Center Boulevard, Winston-Salem, NC, 27101, USA.
Parker-Autry C; Department of Urology, Atrium Health Wake Forest Baptist Hospital, 1 Medical Center Boulevard, Winston-Salem, NC, 27101, USA.
Matthews C; Department of Urology, Atrium Health Wake Forest Baptist Hospital, 1 Medical Center Boulevard, Winston-Salem, NC, 27101, USA. camatthe@wakehealth.edu.

Int Urogynecol J ; 35(1): 119-126, 2024 Jan.

Article en En | MEDLINE | ID: mdl-37991564

Asunto(s)

Toxinas Botulínicas Tipo A; Vejiga Urinaria Hiperactiva; Humanos; Vejiga Urinaria Hiperactiva/diagnóstico; Inyecciones; Dolor/tratamiento farmacológico; Resultado del Tratamiento

Palabras clave

Botox; Overactive bladder; Pain; Urinary incontinence

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Toxinas Botulínicas Tipo A / Vejiga Urinaria Hiperactiva Límite: Humans Idioma: En Revista: Int Urogynecol J Asunto de la revista: GINECOLOGIA / UROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google